ZA200801667B - Novel pharmaceutical combinations for the treatment of respiratory disorders - Google Patents

Novel pharmaceutical combinations for the treatment of respiratory disorders

Info

Publication number: ZA200801667B
Authority: ZA; South Africa
Prior art keywords: treatment; respiratory disorders; novel pharmaceutical; pharmaceutical combinations; combinations
Prior art date: 2005-10-10

Application number

ZA200801667A

Other languages

English (en)

Inventor

Bouyssou Thierry

Michael P Pieper

Schnapp Andreas

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-10

Filing date

2008-02-20

Publication date

2009-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35658907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200801667(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-20 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2009-03-25 Publication of ZA200801667B publication Critical patent/ZA200801667B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Dispersion Chemistry (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200801667A 2005-10-10 2008-02-20 Novel pharmaceutical combinations for the treatment of respiratory disorders ZA200801667B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05109374		2005-10-10

Publications (1)

Publication Number	Publication Date
ZA200801667B true ZA200801667B (en)	2009-03-25

Family

ID=35658907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200801667A ZA200801667B (en)	2005-10-10	2008-02-20	Novel pharmaceutical combinations for the treatment of respiratory disorders

Country Status (23)

Country	Link
US (10)	US20070086957A1 (fr)
EP (1)	EP1940409B1 (fr)
JP (1)	JP5081158B2 (fr)
KR (1)	KR101344225B1 (fr)
CN (1)	CN101282729A (fr)
AR (1)	AR057148A1 (fr)
AT (1)	ATE482709T1 (fr)
AU (1)	AU2006301329B9 (fr)
BR (1)	BRPI0617269A2 (fr)
CA (1)	CA2624584C (fr)
CY (1)	CY1111022T1 (fr)
DE (1)	DE502006007982D1 (fr)
DK (1)	DK1940409T3 (fr)
ES (1)	ES2353404T3 (fr)
IL (1)	IL190652A (fr)
NZ (1)	NZ567547A (fr)
PL (1)	PL1940409T3 (fr)
PT (1)	PT1940409E (fr)
RU (1)	RU2436578C2 (fr)
SI (1)	SI1940409T1 (fr)
TW (1)	TWI396541B (fr)
WO (1)	WO2007042467A1 (fr)
ZA (1)	ZA200801667B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7056916B2 (en) *	2002-11-15	2006-06-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) *	2004-04-22	2005-12-08	Boehringer Ingelheim International Gmbh	Novel medicaments for the treatment of respiratory diseases
US7220742B2 (en)	2004-05-14	2007-05-22	Boehringer Ingelheim International Gmbh	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) *	2004-05-14	2005-11-17	Boehringer Ingelheim International Gmbh	Powder formulations for inhalation, comprising enantiomerically pure beta agonists
BRPI0614410A2 (pt) *	2005-08-15	2011-03-29	Boehringer Ingelheim Int	processo para preparação de betamiméticos
EP2413902B1 (fr)	2009-03-18	2019-07-17	Incarda Therapeutics, Inc.	Doses unitaires, aérosols, trousses, et méthodes pour traiter des affections cardiaques par administration pulmonaire
WO2014016548A2 (fr)	2012-07-27	2014-01-30	Cipla Limited	Composition pharmaceutique
EP2906218B1 (fr)	2012-10-09	2016-12-14	Boehringer Ingelheim International GmbH	Agoniste des récepteurs 2-adrénergiques utilisé dans le traitement de la toux
GB2552856A (en)	2016-02-01	2018-02-14	Incarda Therapeutics Inc	Combining electronic monitoring with inhaled pharmacological therapy to manage atrial arrhythmias including atrial fibrillation
US20200069679A1 (en) *	2016-12-12	2020-03-05	Boehringer Ingelheim International Gmbh	Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
CA3060702A1 (fr)	2017-05-10	2018-11-15	Incarda Therapeutics, Inc.	Doses unitaires, aerosols, trousses, et methodes pour traiter des affections cardiaques par administration pulmonaire
EP3768378B1 (fr)	2018-03-22	2025-08-06	InCarda Therapeutics, Inc.	Nouvelle méthode pour ralentir le rythme ventriculaire
US11020384B2 (en)	2019-08-01	2021-06-01	Incarda Therapeutics, Inc.	Antiarrhythmic formulation
WO2021211850A1 (fr) *	2020-04-16	2021-10-21	Anovent Pharmaceutical(U.S.)., Llc	Formulation inhalable d'une solution contenant de l'olodatérol

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
GB2178965B (en)	1985-07-30	1988-08-03	Glaxo Group Ltd	Devices for administering medicaments to patients
SE453566B (sv)	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
DE3931041C2 (de) *	1989-09-16	2000-04-06	Boehringer Ingelheim Kg	Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SG45171A1 (en)	1990-03-21	1998-01-16	Boehringer Ingelheim Int	Atomising devices and methods
ES2129117T3 (es) *	1992-12-09	1999-06-01	Boehringer Ingelheim Pharma	Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
DE4318455A1 (de)	1993-06-03	1994-12-08	Boehringer Ingelheim Kg	Kapselhalterung
MX9800125A (es) *	1995-06-27	1998-03-31	Boehringer Ingelheim Kg	Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
KR20080015888A (ko) *	2000-06-28	2008-02-20	테바 파마슈티컬 인더스트리즈 리미티드	카르베딜올
AP1572A (en)	2000-10-12	2006-02-13	Boehringer Ingelheim Pharma	Crystalline monohydrate, method for producing the same and use thereof in the production of a medicament.
US20020122773A1 (en) *	2000-12-20	2002-09-05	Michel Pairet	Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020111363A1 (en) *	2000-10-31	2002-08-15	Karin Drechsel	Inhalable formulation of a solution containing a tiotropium salt
US20020151541A1 (en) *	2000-10-31	2002-10-17	Michel Pairet	Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020193392A1 (en) *	2000-11-13	2002-12-19	Christel Schmelzer	Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
PL208137B1 (pl) *	2001-06-22	2011-03-31	Boehringer Ingelheim Pharma	Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
DE10212264A1 (de) *	2002-03-20	2003-10-02	Boehringer Ingelheim Pharma	Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214263A1 (de) *	2002-03-28	2003-10-16	Boehringer Ingelheim Pharma	HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US20030225089A1 (en) *	2002-04-10	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE10253282A1 (de)	2002-11-15	2004-05-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) *	2002-11-15	2006-06-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Medicaments for the treatment of chronic obstructive pulmonary disease
US7250426B2 (en) *	2002-11-29	2007-07-31	Boehringer Ingelheim Pharma Gmbh & Co Kg	Tiotropium-containing pharmaceutical combination for inhalation
US20050025718A1 (en) *	2003-07-31	2005-02-03	Boehringer Ingelheim International Gmbh	Medicaments for inhalation comprising an anticholinergic and a betamimetic
US7244728B2 (en) *	2004-03-17	2007-07-17	Boehringer Ingelheim International Gmbh	Long acting betamimetics for the treatment of respiratory diseases
DK2422786T3 (da) *	2004-04-22	2014-11-17	Boehringer Ingelheim Int	Nye lægemiddelkombinationer til behandling af luftvejssygdomme
US20050272726A1 (en) *	2004-04-22	2005-12-08	Boehringer Ingelheim International Gmbh	Novel medicaments for the treatment of respiratory diseases
US7220742B2 (en) *	2004-05-14	2007-05-22	Boehringer Ingelheim International Gmbh	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) *	2004-05-14	2005-11-17	Boehringer Ingelheim International Gmbh	Aerosol formulation for the inhalation of beta-agonists
US20050255050A1 (en) *	2004-05-14	2005-11-17	Boehringer Ingelheim International Gmbh	Powder formulations for inhalation, comprising enantiomerically pure beta agonists

2006
- 2006-10-05 TW TW095137032A patent/TWI396541B/zh active
- 2006-10-05 US US11/543,694 patent/US20070086957A1/en not_active Abandoned
- 2006-10-06 CN CNA2006800377355A patent/CN101282729A/zh active Pending
- 2006-10-06 AU AU2006301329A patent/AU2006301329B9/en active Active
- 2006-10-06 DE DE502006007982T patent/DE502006007982D1/de active Active
- 2006-10-06 AT AT06807024T patent/ATE482709T1/de active
- 2006-10-06 JP JP2008535000A patent/JP5081158B2/ja active Active
- 2006-10-06 WO PCT/EP2006/067122 patent/WO2007042467A1/fr not_active Ceased
- 2006-10-06 PL PL06807024T patent/PL1940409T3/pl unknown
- 2006-10-06 AR ARP060104404A patent/AR057148A1/es not_active Application Discontinuation
- 2006-10-06 CA CA2624584A patent/CA2624584C/fr not_active Expired - Fee Related
- 2006-10-06 NZ NZ567547A patent/NZ567547A/en unknown
- 2006-10-06 PT PT06807024T patent/PT1940409E/pt unknown
- 2006-10-06 EP EP06807024A patent/EP1940409B1/fr active Active
- 2006-10-06 ES ES06807024T patent/ES2353404T3/es active Active
- 2006-10-06 BR BRPI0617269-5A patent/BRPI0617269A2/pt not_active Application Discontinuation
- 2006-10-06 DK DK06807024.2T patent/DK1940409T3/da active
- 2006-10-06 SI SI200630836T patent/SI1940409T1/sl unknown
- 2006-10-06 RU RU2008117834/15A patent/RU2436578C2/ru active
2008
- 2008-02-20 ZA ZA200801667A patent/ZA200801667B/xx unknown
- 2008-04-07 IL IL190652A patent/IL190652A/en active IP Right Grant
- 2008-05-08 KR KR1020087011117A patent/KR101344225B1/ko active Active
2010
- 2010-12-20 CY CY20101101170T patent/CY1111022T1/el unknown
2011
- 2011-02-16 US US13/028,434 patent/US20110135582A1/en not_active Abandoned
2012
- 2012-06-29 US US13/537,589 patent/US20120263655A1/en not_active Abandoned
2013
- 2013-03-12 US US13/796,445 patent/US20130189194A1/en not_active Abandoned
- 2013-11-04 US US14/071,035 patent/US20140056823A1/en not_active Abandoned
2014
- 2014-06-12 US US14/302,780 patent/US20140286879A1/en not_active Abandoned
- 2014-12-03 US US14/559,030 patent/US20150086489A1/en not_active Abandoned
2016
- 2016-06-09 US US15/177,513 patent/US20160287600A1/en not_active Abandoned
2017
- 2017-01-23 US US15/412,251 patent/US20170128455A1/en not_active Abandoned
- 2017-08-16 US US15/678,286 patent/US20170340645A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW200731975A (en)	2007-09-01
EP1940409B1 (fr)	2010-09-29
NZ567547A (en)	2011-06-30
US20170128455A1 (en)	2017-05-11
US20070086957A1 (en)	2007-04-19
TWI396541B (zh)	2013-05-21
IL190652A (en)	2013-10-31
RU2008117834A (ru)	2010-01-27
IL190652A0 (en)	2008-12-29
AU2006301329B9 (en)	2012-09-06
ATE482709T1 (de)	2010-10-15
AU2006301329A1 (en)	2007-04-19
AR057148A1 (es)	2007-11-21
JP2009511541A (ja)	2009-03-19
PL1940409T3 (pl)	2011-03-31
RU2436578C2 (ru)	2011-12-20
CA2624584C (fr)	2017-01-03
KR101344225B1 (ko)	2013-12-23
DE502006007982D1 (de)	2010-11-11
SI1940409T1 (sl)	2010-12-31
US20160287600A1 (en)	2016-10-06
PT1940409E (pt)	2010-12-03
US20150086489A1 (en)	2015-03-26
US20110135582A1 (en)	2011-06-09
AU2006301329B2 (en)	2012-08-02
CN101282729A (zh)	2008-10-08
CA2624584A1 (fr)	2007-04-19
BRPI0617269A2 (pt)	2011-07-19
US20170340645A1 (en)	2017-11-30
EP1940409A1 (fr)	2008-07-09
DK1940409T3 (da)	2010-11-29
JP5081158B2 (ja)	2012-11-21
CY1111022T1 (el)	2015-06-11
US20120263655A1 (en)	2012-10-18
KR20080067643A (ko)	2008-07-21
ES2353404T3 (es)	2011-03-01
US20140056823A1 (en)	2014-02-27
US20130189194A1 (en)	2013-07-25
US20140286879A1 (en)	2014-09-25
WO2007042467A1 (fr)	2007-04-19

Publication	Publication Date	Title
ZA200801667B (en)	2009-03-25	Novel pharmaceutical combinations for the treatment of respiratory disorders
IL187168A0 (en)	2008-02-09	Improved nanobodiestm for the treatment of aggregation-mediated disorders
TWI369987B (en)	2012-08-11	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
IL188204A0 (en)	2008-03-20	Combination therapy for the treatment of immunoinflammatory disorders
ZA200802762B (en)	2015-11-25	Pharmaceutical compositions for the treatment of inner ear disorders
ZA200706791B (en)	2012-01-25	Isoxazole combretasin derivatives for the treatment of disorders
IL184425A0 (en)	2007-10-31	Cxcr4 antagonists for the treatment of medical disorders
IL191283A (en)	2015-03-31	Compositions for treating eye irregularities
GB0522311D0 (en)	2005-12-07	Pharmaceutical compositions for the treatment of pain
IL190338A0 (en)	2009-09-22	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
IL185052A0 (en)	2007-12-03	Treatment of bone disorders
IL190920A0 (en)	2009-09-22	Compounds for the treatment of metabolic disorders
EP2166837A4 (fr)	2011-12-21	Combinaison médicamenteuse utilisable pour le traitement de troubles cutanés
ZA200901523B (en)	2010-05-26	Use of extracts for the treatment of viral disorders
TWI372056B (en)	2012-09-11	Novel medicament combinations for the treatment of respiratory diseases
GB0410399D0 (en)	2004-06-16	The treatment of respiratory disease
GB0410398D0 (en)	2004-06-16	The treatment of respiratory disease
IL185444A0 (en)	2008-01-06	Novel drugs for treating respiratory diseases
IL193799A0 (en)	2009-09-22	New therapeutic combinations for the treatment or prevention of psycotic disorders
PL1982178T3 (pl)	2014-02-28	Sposoby leczenia zaburzeń afektywnych
ZA200805108B (en)	2009-03-25	Treatment of neurodegenerative disorders
ZA200802270B (en)	2009-02-25	Treatment of neurodegenerative disorders
HU0500145D0 (en)	2005-04-28	Composition for the treatment of oral diseases
GB0512757D0 (en)	2005-07-27	Treatment of respiratory disorders
GB0417474D0 (en)	2004-09-08	Treatment of respiratory disorders